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Abstract
Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized
that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine. We tested this hypothesis by using
two patient-derived xenograft models (designated J and F) and the pancreatic cancer stem cell markers CD24, CD44,
and ESA.We determined the percentage ofmarker-positive cells and their tumor-initiating capacity (by limiting dilution
assays) after treatment with gemcitabine and the Chk1 inhibitor, AZD7762. We found that marker-positive cells were
significantly reduced by the combination of gemcitabine and AZD7762. In addition, secondary tumor initiation was
significantly delayed in response to primary tumor treatment with gemcitabine + AZD7762 compared with control,
gemcitabine, or AZD7762 alone. Furthermore, for the same number of stem cells implanted from gemcitabine−
versus gemcitabine + AZD7762-treated primary tumors, secondary tumor initiation at 10 weeks was 83% versus
43%, respectively. We also found that pS345 Chk1, which is a measure of DNA damage, was induced in marker-
positive cells but not in the marker-negative cells. These data demonstrate that Chk1 inhibition in combination with
gemcitabine reduces both the percentage and the tumor-initiating capacity of pancreatic cancer stem cells. Further-
more, the finding that the Chk1-mediated DNA damage response was greater in stem cells than in non–stem cells
suggests that Chk1 inhibition may selectively sensitize pancreatic cancer stem cells to gemcitabine, thus making
Chk1 a potential therapeutic target for improving pancreatic cancer therapy.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death
and remains one of the least curable cancers with an overall 5-year
survival rate of less than 5% [1]. Although a recent study has
shown that the combination of 5-fluorouracil, leucovorin, irinotecan,
and oxaliplatin (FOLFIRINOX) is superior to gemcitabine for
high-performance status patients with metastatic pancreatic cancer,
gemcitabine still plays a key role in the management of metas-
tatic and nonmetastatic, locally advanced disease [2,3]. A number
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of clinical trials have attempted to improve gemcitabine-based chemo-
therapy, but very few have produced clinically significant survival
advantages [4–6].
Inhibition of the DNA damage response is a promising strategy for
sensitizing tumor cells to therapy. Under the regulation of ATR/
ATM, checkpoint kinase 1 (Chk1) functions as an integral compo-
nent of the DNA damage response by mediating cell cycle arrest and
DNA damage repair. A number of small-molecule Chk1 inhibitors
have been recently developed including, AZD7762, SCH900776,
LY2606368, and LY2603618 [7–9]. We have previously demonstrated
that inhibition of Chk1 sensitizes pancreatic cancer cells and tumors
to gemcitabine by mechanisms including G2 checkpoint abrogation
and homologous recombination repair (HRR) inhibition [10,11].
In addition, tumor cells that harbor aberrations in other DNA dam-
age response machinery (i.e., p53, p16, Rb) and thus do not arrest
at G1 in response to DNA damage will be selectively affected by
Chk1 inhibition. Conversely, normal cells will be protected from
Chk1 inhibition by their other intact checkpoints (i.e., p53-mediated
G1 arrest) [12–15].
Although the role of Chk1 inhibition in sensitizing pancreatic
tumor cells to gemcitabine has been extensively explored [11,16],
the potentially crucial role of cancer stem cells has not been investi-
gated. Especially in the context of pancreatic cancer, where even com-
plete surgical resection is often quickly followed by disease progression,
therapies targeted to tumor initiation (versus tumor growth) are
necessary. Pancreatic cancer stem cells were recently identified by
expression of the cell surface markers CD24, CD44, and ESA
(epithelial-specific antigen) [17]. Because pancreatic cancer stem cells
are refractory to conventional chemotherapy and radiotherapy [18,19],
approaches to target both bulk cancer cells and cancer stem cells are
important in improving the efficacy of current therapies.
The concept of selectively sensitizing cancer stem cells to chemo-
therapy and/or radiotherapy has generated great enthusiasm in the
oncology community but thus far has yielded only a few successes
[20,21]. Chk1/2 inhibition sensitizes human glioma cancer stem
cells to radiation [22]. This study demonstrated that cancer stem
cells possess enhanced cell cycle checkpoint activity in response to
radiation and more effectively repair radiation-induced DNA damage
than non–stem cells. In addition, ATR or Chk1 inhibition sensitizes
colon cancer stem cells to cisplatin [23]. This study and others sug-
gest that the resistance of cancer stem cells to therapy is mediated by
more robust DNA damage response and repair pathways [21,24,25];
hence, it seems logical to target these pathways to overcome ther-
apy resistance. Because Chk1 inhibition has been shown to inhibit
both the DNA damage–induced cell cycle checkpoint response and
homologous recombination repair [16,26], it is a promising target for
sensitizing cancer stem cells to DNA-damaging agents.
Thus, the goal of the present study was to determine whether
Chk1 inhibition could sensitize pancreatic cancer stem cells to gem-
citabine. We used two low-passage primary patient xenograft models
to determine the effects of gemcitabine and the Chk1 inhibitor,
AZD7762, on the percentage of CD24, CD44, ESA-positive cells
and their functionality. We found that the combination of gemcitabine
and AZD7762 significantly reduced the percentage of marker-positive
cells and decreased the tumor-initiating capacity of cancer stem cells
using a limiting dilution assay. Further, we determined that Chk1 in-
hibition played a specific role in the DNA damage response, overall




Samples of human pancreatic adenocarcinomas were obtained
within 30 minutes after surgical resection according to institutional
review board–approved guidelines as previously described [17].
Briefly, tumors were mechanically dissociated into 2 × 2-mm pieces
and implanted surgically into the mid abdomen of NOD/SCID
mice. After engraftment into mice, single-cell suspensions were
created from surgically resected xenografts by mechanical mincing
in RPMI containing penicillin/streptomycin followed by a 1-hour
incubation at 37°C with 1 U/μl of collagenase type IV (Worthington
Biochemical Corp, Lakewood, NJ) with constant agitation. Cells were
filtered consecutively through 100- and 40-μm polypropylene cell
strainers (BD, Franklin Lakes, NJ). Tumor cells (1 × 106) were sus-
pended in a 1:1 mixture of 10% fetal bovine serum-RPMI–Matrigel
(BD Biosciences, San Jose, CA) and injected subcutaneously into the
right and left flanks of NOD/SCIDmice. Animals were handled accord-
ing to a protocol approved by the University of Michigan Committee
for Use and Care of Animals.
In Vivo Treatment
AZD7762 was dissolved in 11.3% 2-hydroxyproply-β-cyclodextrin
(Sigma, St Louis, MO) and sterile saline, and the pH was adjusted to
4.0. Gemcitabine was dissolved in sterile saline. Treatment was initiated
when the average tumor volume reached approximately 200 mm3.
Mice were administered gemcitabine (90 mg/kg, intraperitoneally,
Mon and Thu) and/or AZD7762 (20 mg/kg, intraperitoneally, Mon,
Tue, Thu, and Fri) for three cycles. Tumor size was measured two
times per week. Tumor volume (TV) was calculated according to the
equation: TV = π/6 (ab2), where a and b are the longer and shorter
dimensions of the tumor, respectively.
FACS Analyses
Tumor cell suspensions were washed twice with Hank’s balanced
salt solution (HBSS) containing 2% fetal bovine serum, penicillin,
and streptomycin and resuspended at a cell concentration of 1 × 106
cells per 100 μl of HBSS. Cells were stained with the following anti-
bodies at a 1:50 dilution: CD24-FITC, CD44-PE (BD Biosciences),
and ESA/CD326 (EpCAM)-APC (Miltenyi Biotec, Cambridge, MA)
as well as a 1:100 dilution of H2k-d-PE-Cy5 antibody (BD Bio-
sciences) for 20 to 30 minutes on ice, protected from light. Dead cells
were excluded by DAPI staining (0.75 μg/ml). Stained cells were again
washed twice with HBSS before FACS analyses/sorting in MoFlo
(Becton and Dickenson) with SUMMIT software (version 5.3.0; Dako).
Unstained samples were used to set gates. Side scatter and forward scatter
profiles were used to eliminate cell doublets.
Immunoblot Analysis
Single cells from untreated tumor xenografts were stained for CD24,
CD44, ESA and FACS sorted for DAPI− (viable), H2k-d− (human),
CD24+, CD44+, ESA+ cells or only for DAPI−, H2k-d− cells.
The sorted cells were immediately treated ex vivo with gemcitabine
(250 nM, t = 0-2 hours) and/or AZD7762 (100 nM, t = 24-30 hours).
At the end of treatment, cells were lysed in SDS lysis buffer contain-
ing protease (Roche, Indianapolis, IN) and phosphatase inhibitors
(Sigma). Cellular protein levels in the extracts were measured using a
BCA kit (Thermo Scientific, Rockford, IL). Fifteen micrograms of total
cellular protein was separated on NuPAGE Novex 4% to 12% Bis-Tris
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Midi gel and electroblotted onto a polyvinylidene difluoride membrane.
Blots were incubated with primary antibodies to phosphorylated Chk1
(S345), Chk1 (total), and GAPDH (Cell Signaling, Danvers, MA) and
followed by secondary horseradish peroxidase–conjugated anti-rabbit
IgG antibody (Cell Signaling). Immunoreactive bands were visualized
by SuperSignal WestDura chemiluminescence (Pierce).
Statistical Analysis
The percentages of CD24, CD44, ESA-positive cells were compared
between treatments using ANOVA models with Tukey post hoc test in
GraphPad Prism, version 5.0c (GraphPad Software, Inc, La Jolla, CA).
Tumor initiation was determined for each xenograft by identifying the
earliest day on which a tumor volume was larger than 20 mm3. The
Kaplan-Meier method was used to calculate the median initiation times.
Cox proportional hazards regression was used to model tumor initiation
as a function of treatments, the number of viable human cells, or the num-
ber of marker-positive cells. The mixed linear model with random slopes
and intercepts was applied to the log-transformed tumor volumes to com-
pare tumor growth rates (after initiation) between treatment arms. Analy-
ses on tumor initiation and tumor growth were conducted using SAS
(version 9.3; SAS Institute, Cary, NC). Results are presented as mean ±
SE unless otherwise stated. Data with P < .05 were considered significant.
Results
To begin to determine whether inhibition of Chk1 might sensitize
pancreatic cancer stem cells to gemcitabine, we treated mice bearing
subcutaneous p53 mutant, pancreatic tumor xenografts designated
“patient J” and “patient F” for three cycles with the Chk1 inhibitor,
AZD7762 (Mon, Tue, Thu, Fri) and gemcitabine (Mon and Thu), as
illustrated in Figure 1A. During treatment, we found that AZD7762,
in combination with gemcitabine, produced significant tumor growth
inhibition (Figure 1, B and C), which is consistent with our previous
tumor growth experiments demonstrating that AZD7762 sensitizes
these patient-derived pancreatic tumor xenografts to gemcitabine [11].
On the last day of treatment, the percentage of CD24, CD44, ESA-
positive cells (stem cell markers previously identified by our group in
patient-derived pancreatic tumor xenografts [17]) was analyzed. We
found in patient J–derived xenografts that neither gemcitabine nor
AZD7762 significantly reduced the percentage of marker-positive cells
(Figure 1D). However, the combination of gemcitabine with AZD7762
led to a significant depletion of the marker-positive cells, suggest-
ing that AZD7762 may sensitize pancreatic cancer stem cells to gem-
citabine. We went on to determine the effects of gemcitabine and
AZD7762 on CD24, CD44, ESA-positive cells in an independent
model, patient F, and found that gemcitabine or AZD7762 alone
reduced the percentage of marker-positive cells (Figure 1E). However,
Figure 1. Reduction in the percentage of CD24, CD44, and ESA-positive cells by gemcitabine and AZD7762. NOD/SCID mice bearing
patient J– (B) or patient F– (C) derived early-passage xenografts were treated with gemcitabine (90 mg/kg) and/or AZD7762 (20 mg/kg) as
illustrated (A). Tumor volumes as a function of increasing time from treatment initiation are shown. On the last day of treatment, tumors
were harvested, and the percentages of viable, human cells positive for the indicated markers (CD44-PE, ESA-APC, and CD24-FITC)
were analyzed by FACS in patient J– (D) and patient F– (E) derived xenografts. Data are the mean of n = 3 to 8 tumors per treatment
condition ± SE. Statistically significant differences (P < .05) are indicated versus *control, †gemcitabine, and ¥AZD7762.
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the combination of gemcitabine with AZD7762 produced maximal
depletion of marker-positive cells, which was significant, compared with
control-, gemcitabine-, or AZD7762-alone treatment conditions. These
data support the hypothesis that Chk1 inhibition sensitizes pancreatic
cancer stem cells to gemcitabine.
To further test the hypothesis that Chk1 inhibition sensitizes pan-
creatic cancer stem cells to gemcitabine, we conducted a secondary
tumor initiation assay with primary tumor cells that had previously
been treated with gemcitabine and AZD7762 as described in Figure 1.
After three cycles of treatment with gemcitabine and/or AZD7762,
primary tumor cells were analyzed for their percentage of CD24,
CD44, ESA-positive cells (Figure 1D) and then reimplanted at limit-
ing dilutions into secondary mice. The time required for initiation of
secondary tumors, after implantation with an equal number of viable
tumor cells (i.e., containing both stem cells and non–stem cells), was
monitored for each of the treatment groups. We found that treatment
with gemcitabine or AZD7762 alone significantly delayed secondary
tumor initiation (Figure 2A). More importantly, tumor initiation was
significantly delayed in response to the combination of gemcitabine
with AZD7762 compared with control, gemcitabine, or AZD7762
alone (P < .05). We further analyzed these data by the number of
marker-positive stem cells implanted. We found that, for a similar
number of marker-positive stem cells implanted, treatment with gem-
citabine and AZD7762 led to delayed tumor initiation relative to
control or AZD7762 alone (P < .05; Figure 2B). This difference in
tumor initiation in response to gemcitabine + AZD7762 is further
illustrated by a comparison of the tumor initiation at 10 weeks after
implantation for a given number of stem cells (n = 3150; Figure 2C).
In response to primary tumor treatment with gemcitabine, 10 (83%)
of 12 secondary tumors had initiated by 10 weeks, whereas in response
to gemcitabine + AZD7762, only 3 (43%) of 7 tumors had initiated.
These data demonstrate that treatment of primary tumors with gem-
citabine in combination with AZD7762 reduces both functional stem
cells (i.e., the ability to generate a tumor) and the apparent viability of
marker-positive stem cells.
Having shown that the combination of gemcitabine and AZD7762
decreased the fraction of surviving functional stem cells and the viabil-
ity of marker-positive stem cells, we wished to determine whether the
drug combination affected the ability of the marker-positive cells that
did survive to promote tumor growth. Therefore, we monitored the
growth rate of secondary tumors as well as their percentage of CD24,
CD44, ESA-positive cells (Figure 3). Despite the ability of gemcitabine
and AZD7762 to reduce the percentage CD24, CD44, ESA-positive
cells as well as their tumor-initiating capacity (Figures 1 and 2), secondary
tumor growth rates were similar across all treatment groups. To de-
termine whether the reduction in CD24, CD44, ESA-positive cells
observed in primary tumors was maintained, secondary tumors were
assessed for their percentage of CD24, CD44, ESA-positive cells. We
found that secondary tumors originating from gemcitabine- and gem-
citabine + AZD7762–treated primary tumors maintained significantly
Figure 2. Inhibition of secondary tumor initiation in response to primary tumor treatment with gemcitabine and AZD7762 treatment. Single
cells derived from the patient J xenografts (from Figure 1A) were reimplanted into secondary mice at 250, 50, 10, and 1 × 103 human viable
cells. Animals were monitored twice weekly for tumor initiation for up to 5 months. Tumors ≥ 20 mm3 were scored as “initiated.” The
median time for tumor initiation in days is shown as a function of the number of bulk cells reimplanted (A) or the number of marker-positive
stem cells reimplanted (B). A summary of the actual number of CD24, CD44, ESA-positive cells implanted (in parentheses) and the
corresponding tumor initiation at 10 weeks after implantation is shown (C). Data are from 8 to 12 tumors per treatment condition per cell
concentration. Statistically significant differences (P < .05) are indicated versus *control, †gemcitabine, and ¥AZD7762.
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reduced percentages of marker-positive cells. Taken together, these
results demonstrate that treatment with gemcitabine and AZD7762
produces lasting inhibitory effects on both the percentage and the
tumor-initiating capacity of CD24, CD44, ESA-positive cells. How-
ever, once a tumor is able to initiate, previous combination treatment
does not affect the tumor growth rates.
To begin to determine the mechanisms and selectivity of Chk1 in-
hibition for sensitizing pancreatic cancer stem cells to gemcitabine,
we assessed the Chk1-mediated DNA damage response on the cancer
stem cell and non–cancer stem cell populations within the tumor (Fig-
ure 4). After sorting these two cell populations, cells were ex vivo treated
with gemcitabine and AZD7762 according to previously established
concentrations and treatment schedules and using S345 Chk1 phos-
phorylation as a pharmacodynamic biomarker of AZD7762-mediated
DNA damage [11]. Consistent with our previous observations in bulk
pancreatic cancer cells and tumors [11], we found in response to
AZD7762 alone or in combination with gemcitabine that phospho-
rylation of Chk1 (S345) was induced. Whereas phosphorylation was
maximal in response to gemcitabine and AZD7762, this occurred only
in the marker-positive cancer stem cells and not in the human, viable
bulk cancer cell population. These data suggest that CD24, CD44,
ESA-positive pancreatic cancer stem cells encounter a greater degree
of DNA damage in response to Chk1 inhibition and thus elicit a more
robust DNA damage response and are consistent with the observed
sensitization to gemcitabine by Chk1 inhibition in our in vivo studies.
Discussion
In this study, we have found that the combination of gemcitabine with
a Chk1 inhibitor (AZD7762) decreases both the number of pancreatic
cancer stem cells and the tumor-initiating capacity of the cancer stem
cell population. These findings suggest that Chk1 inhibition may be a
useful strategy for overcoming therapy resistance in pancreatic cancer
and for preventing tumor recurrence. In addition, this study demon-
strates a heightened DNA damage response in stem cells (vs non–
stem cells) after Chk1 inhibition, suggesting a greater extent of DNA
damage in the stem cells, which is consistent with their sensitization
to gemcitabine by Chk1 inhibition.
In our previous work, we have extensively explored the use of Chk1
inhibition as a means of sensitizing bulk pancreatic tumor cells to
gemcitabine and radiation therapy primarily through mechanisms in-
volving G2 checkpoint abrogation and inhibition of HRR and, more
specifically, demonstrated that AZD7762 significantly inhibits tumor
growth in response to gemcitabine in the patient-derived tumors
used in this study [11,16]. This sensitizing effect of AZD7762 to
gemcitabine on bulk tumor growth was not apparent in this study
owing to the short tumor monitoring period before tumor harvesting
for stem cell analysis. We and others have found sensitization in
response to Chk1 inhibition to occur selectively in tumor cells that is
in part attributable to the presence of mutant p53 [27,28]. Although
Figure 4. Enhanced Chk1-mediated DNA damage response in pan-
creatic cancer stem cells. Single cells derived from patient J early-
passage xenografts were FACS sorted to obtain human (H2kD−),
viable (DAPI−), CD24, CD44, ESA-positive cells, or human viable
cells. After FACS sorting, cells were treated ex vivowith gemcitabine
(250 nM, t = 0-2 hours) and/or AZD7762 (100 nM, t = 24-30 hours)
and then prepared for immunoblot analysis for the indicated pro-
teins. Data are from a single representative experiment.
Figure 3. Secondary tumors display similar growth rates but altered percentages of marker positive in response to primary gemcitabine
and AZD7762 treatments. (A) The tumor growth kinetics of secondary xenografts implanted from gemcitabine- and/or AZD7762-treated
primary tumors are illustrated. Data are the mean ± SE of 9 to 12 tumors per treatment condition and are expressed relative to the
day of initiation (defined by a tumor ≥ 20 mm3). (B) Secondary tumors reaching a volume of approximately 400 mm3 were harvested
and analyzed for CD24, CD44, and ESA. Data are the mean ± SE of 14 to 28 tumors per condition. Statistically significant differences
(P < .05) are indicated versus *control and ¥AZD7762.
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AZD7762 inhibits both Chk1 and Chk2, previous studies from our
group and others suggest that sensitization is attributable to Chk1 but
not Chk2 inhibition [10,16,29–33]. In the current study, we present
an additional mechanism of tumor sensitization to gemcitabine by
Chk1 inhibition through selective targeting of pancreatic cancer stem
cells. Given the important roles these DNA damage responses play in
stem cells, targeting them represents a potentially highly effective treat-
ment strategy. Our data suggest that Chk1 inhibition may preferentially
target these overactivated DNA damage response pathways in cancer
stem cells, thereby sensitizing them to therapy.
While CD24, CD44, and ESA positivity was the first reported
set of markers to enrich for pancreatic cancer stem cells [17], several
other markers have been found to identify pancreatic cancer stem cells
since then. CD133 defines cancer stem cells from patient-derived pan-
creatic tumors [18]. In addition, high ALDH activity has been shown
by several laboratories to enrich for pancreatic cancer stem cells [34,35]
and, in one case, to be superior to CD133. More recently, some of
these markers have been identified as potential therapeutic targets.
Notably, inhibition of ALDH has been shown to sensitize ALDHhigh
cancer cells (breast and ovarian) to chemotherapy and radiotherapy
[36,37], which may be through mechanisms involving an increase
in reactive oxygen species (ROS) [38]. Taken together, these results
suggest that there are multiple markers that define pancreatic cancer
stem cells. It will be important to understand how these different
markers relate to each other and to the cancer stem cell phenotype.
Previous studies have reported that cancer stem cells are resistant to
chemotherapies [39] such as gemcitabine in the case of pancreatic
cancer stem cells [40,41]. In particular, these studies demonstrated
that pancreatic cancer stem cell markers were either enriched or un-
affected by gemcitabine treatment. Our present findings demonstrate
that gemcitabine does not significantly increase the percentage of CD24,
CD44, ESA-positive cells. Furthermore, pancreatic cancer stem cells
are sensitive to gemcitabine because we found that secondary tumor
initiation is delayed in response to gemcitabine. Thus, although many
studies have found that cancer stem cells are relatively resistant to
therapy, the current study and our previous findings regarding the sen-
sitivity of some breast cancer stem cells to radiation [42] suggest that it is
premature to conclude that cancer stem cell resistance is universal.
Although the combination of gemcitabine and AZD7762 reduced
both the percentage of marker-positive cells and their tumor-initiating
capacity, after tumor initiation, tumor growth rates were similar across
treatment groups (Figure 3A). These data are consistent with the
hypothesis that, after tumor initiation, tumor growth is independent
of the initial number and viability of the stem cells. Progenitor cells
that are produced by asymmetrical division with stem cells retain pro-
liferative capacity for a limited number of generations, and it seems
possible that these cells could support tumor growth during our obser-
vation period. Given that none of the treatments used in this study
completely eradicated the pancreatic cancer stem cells or their tumor-
initiating capacity, it is conceivable that, in the absence of any treatment
on the secondary tumors, the cancer stem cells may recover to a thresh-
old level that is adequate to support tumor growth. We must also
entertain the possibility that there are additional stem cells that are
not detected by CD24, CD44, ESA positivity, although the correla-
tion between marker-positive cells and primary tumor initiation would
suggest that maker positivity does, in general, correlate with a stem-
like property.
Other studies have shown that cancer stem cells elicit a more robust
Chk1-mediated DNA damage response than non–stem cells [22,23,25].
Consistent with these observations, we found that Chk1 inhibition
had a more profound effect on cancer stem cells as evidenced by
greater pChk1 (S345) accumulation in the marker-positive versus the
human viable cells. We have previously shown that pChk1 (S345) is
a pharmacodynamic biomarker of gemcitabine-AZD7762 activity,
which is associated with elevated DNA damage in response to this
therapy [11]. Thus, our data suggest that inhibition of Chk1 produces
more DNA damage that is marked by a more robust DNA damage
response in cancer stem cells. It will be important in future studies to
better understand the mechanisms contributing to selective cancer
stem cell sensitization through the incorporation of in vitro pancreatic
cancer stem cell models.
Given that cancer stem cells are generally thought to be resistant
to chemotherapy and radiotherapy, many strategies for sensitizing can-
cer stem cells are emerging. Consistent with our study, small-molecule
inhibitors of ATR or Chk1 sensitized colon cancer stem cells to cis-
platin [23], establishing Chk1 as a promising target. Another potential
mechanism driving the resistance of cancer stem cells to therapy is
through increased DNA damage responses including an increased
capacity for minimizing ROS [43]. Thus, strategies to increase ROS
(by increasing ROS or blocking scavenging) are a promising approach
for sensitizing to radiation. Other studies have shown that the AKT in-
hibitor, perifosine, sensitizes breast cancer stem cells to radiation [21],
whereas targeting DR5, SHH, or mTOR in combination with gem-
citabine reduces pancreatic cancer stem cells [41,44]. Planned and
ongoing trials should soon reveal whether the promising preclinical
results of targeting cancer stem cells could translate into improved
patient outcome.
References
[1] Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W,
Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al. (2011). SEER Cancer
Statistics Review (1975–2008). National Cancer Institute, Bethesda, MD.
[2] Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y,
Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. (2011).
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
364, 1817–1825.
[3] Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P,
Ramanathan RK, Crane CH, Alberts SR, et al. (2011). Gemcitabine alone
versus gemcitabine plus radiotherapy in patients with locally advanced pan-
creatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29,
4105–4112.
[4] Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ,
Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine
compared with gemcitabine alone in patients with advanced pancreatic cancer:
a phase III trial of the National Cancer Institute of Canada Clinical Trials
Group. J Clin Oncol 25, 1960–1966.
[5] Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland
KM, Atkins JN, Mirtsching BC, Rivkin SE, et al. (2010). Phase III study com-
paring gemcitabine plus cetuximab versus gemcitabine in patients with advanced
pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial
S0205. J Clin Oncol 28, 3605–3610.
[6] Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H,
Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, et al. (2010). Gemcitabine
plus bevacizumab compared with gemcitabine plus placebo in patients with
advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B
(CALGB 80303). J Clin Oncol 28, 3617–3622.
[7] Ashwell S and Zabludoff S (2008). DNA damage detection and repair pathways—
recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer
Res 14, 4032–4037.
[8] Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L,
Wiswell D, Seghezzi W, Penaflor E, et al. (2011). Targeting the replication check-
point using SCH 900776, a potent and functionally selective CHK1 inhibitor
identified via high content screening. Mol Cancer Ther 10, 591–602.
524 Chk1 Inhibition in Pancreatic Cancer Stem Cells Venkatesha et al. Neoplasia Vol. 14, No. 6, 2012
[9] Carrassa L and Damia G (2011). Unleashing Chk1 in cancer therapy. Cell Cycle
10, 2121–2128.
[10] Morgan MA, Parsels LA, Parsels JD, Lawrence TS, and Maybaum J (2006).
The relationship of premature mitosis to cytotoxicity in response to checkpoint
abrogation and antimetabolite treatment. Cell Cycle 5, 1983–1988.
[11] Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, HassanMC, Arumugarajah S,
Parsels JD, Hylander-Gans L, Simeone DM, et al. (2011). Assessment of chk1
phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer
Res 17, 3706–3715.
[12] Massey AJ, Borgognoni J, Bentley C, Foloppe N, Fiumana A, and Walmsley L
(2010). Context-dependent cell cycle checkpoint abrogation by a novel kinase
inhibitor. PLoS One 5, e13123.
[13] Ma CX, Janetka JW, and Piwnica-Worms H (2011). Death by releasing the breaks:
CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17, 88–96.
[14] Levesque AA, Fanous AA, Poh A, and Eastman A (2008). Defective p53 sig-
naling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B
repression rendering them sensitive to Chk1 inhibitors that abrogate DNA
damage-induced S and G2 arrest. Mol Cancer Ther 7, 252–262.
[15] Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall
KJ, Aherne GW, Eccles SA, Raynaud FI, et al. (2010). The preclinical pharma-
cology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol
Cancer Ther 9, 89–100.
[16] Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC,
Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. (2010).
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves
abrogation of the G2 checkpoint and inhibition of homologous recombinational
DNA repair. Cancer Res 70, 4972–4981.
[17] Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke
MF, and Simeone DM (2007). Identification of pancreatic cancer stem cells.
Cancer Res 67, 1030–1037.
[18] Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ,
and Heeschen C (2007). Distinct populations of cancer stem cells determine
tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell
1, 313–323.
[19] Simeone DM (2008). Pancreatic cancer stem cells: implications for the treatment
of pancreatic cancer. Clin Cancer Res 14, 5646–5648.
[20] Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F,
Tripodo C, Russo A, Gulotta G, Medema JP, et al. (2007). Colon cancer stem
cells dictate tumor growth and resist cell death by production of interleukin-4.
Cell Stem Cell 1, 389–402.
[21] Zhang M, Atkinson RL, and Rosen JM (2010). Selective targeting of radiation-
resistant tumor-initiating cells. Proc Natl Acad Sci USA 107, 3522–3527.
[22] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW,
Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 444, 756–760.
[23] Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN,
Palagyi A, Eisen C, Ellwart JW, Rivera J, et al. (2011). Inhibition of ataxia
telangiectasia- and Rad3-related function abrogates the in vitro and in vivo
tumorigenicity of human colon cancer cells through depletion of the CD133(+)
tumor-initiating cell fraction. Stem Cells 29, 418–429.
[24] McCord AM, Jamal M, Williams ES, Camphausen K, and Tofilon PJ (2009).
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA dam-
age response compared with established cell lines. Clin Cancer Res 15, 5145–5153.
[25] Eyler CE and Rich JN (2008). Survival of the fittest: cancer stem cells in
therapeutic resistance and angiogenesis. J Clin Oncol 26, 2839–2845.
[26] Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J,
and Helleday T (2005). The cell-cycle checkpoint kinase Chk1 is required for
mammalian homologous recombination repair. Nat Cell Biol 7, 195–201.
[27] Vance SM, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence
T, and Morgan MA (2011). Selective radiosensitization of p53 mutant pancreatic
cancer cells by combined inhibition of Chk1 and PARP1.Cell Cycle 10, 4321–4329.
[28] Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL,
Green S, Haye HR, Horn CL, Janetka JW, et al. (2008). AZD7762, a novel
checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates
DNA-targeted therapies. Mol Cancer Ther 7, 2955–2966.
[29] Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S,
Ninkovic S, Chen P, Nichols T, et al. (2008). Breaching the DNA damage
checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint
kinase 1. Mol Cancer Ther 7, 2394–2404.
[30] Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny
WA, Canman CE, Kraker AJ, Lawrence TS, et al. (2009). Gemcitabine sensitiza-
tion by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA
damage response in pancreatic cancer cells. Mol Cancer Ther 8, 45–54.
[31] Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ,
Vroman BT, Thomas MB, Baek YU, Hopkins KM, et al. (2005). Gemcitabine-
induced activation of checkpoint signaling pathways that affect tumor cell survival.
Mol Pharmacol 68, 1636–1644.
[32] Carrassa L, Broggini M, Erba E, and Damia G (2004). Chk1, but not Chk2, is
involved in the cellular response to DNA damaging agents: differential activity
in cells expressing or not p53. Cell Cycle 3, 1177–1181.
[33] Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, and Wang Y (2001). The radio-
resistance to killing of A1-5 cells derives from activation of the Chk1 pathway.
J Biol Chem 276, 17693–17698.
[34] Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra
JB, Rajeshkumar NV, He X, et al. (2010). Prognostic significance of tumorigenic
cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst
102, 340–351.
[35] Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey
DJ, Evans DB, and Gallick GE (2011). ALDH activity selectively defines
an enhanced tumor-initiating cell population relative to CD133 expression in
human pancreatic adenocarcinoma. PLoS One 6, e20636.
[36] Croker AK and Allan AL (2012). Inhibition of aldehyde dehydrogenase (ALDH)
activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)
CD44 (+) human breast cancer cells. Breast Cancer Res Treat 133, 75–87.
[37] Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL,
Miller LD, Mejia PV, Jennings NB, Gershenson DM, et al. (2010). Targeting
aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9,
3186–3199.
[38] Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B,
Cassidy J, Darling JL, and Wang W (2011). Disulfiram modulated ROS-MAPK
and NFκB pathways and targeted breast cancer cells with cancer stem cell–like
properties. Br J Cancer 104, 1564–1574.
[39] Rasheed ZA, Kowalski J, Smith BD, andMatsuiW (2011). Concise review: emerg-
ing concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883–887.
[40] Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM,
Rubio-Viqueira B, Garcia-Garcia E, Lopez-Rios F, Matsui W, et al. (2009).
A direct pancreatic cancer xenograft model as a platform for cancer stem cell
therapeutic development. Mol Cancer Ther 9, 2582–2592.
[41] Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K,
Matsui WH, and Hidalgo M (2010). A combination of DR5 agonistic mono-
clonal antibody with gemcitabine targets pancreatic cancer stem cells and results
in long-term disease control in human pancreatic cancer model. Mol Cancer
Ther 9, 2582–2592.
[42] Zielske SP, Spalding AC, Wicha MS, and Lawrence TS (2011). Ablation of
breast cancer stem cells with radiation. Transl Oncol 4, 227–233.
[43] Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam
JS, Ailles LE, Wong M, et al. (2009). Association of reactive oxygen species
levels and radioresistance in cancer stem cells. Nature 458, 780–783.
[44] Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber
S, Ellwart JW, Mustafa M, Bartenstein P, D’Haese JG, et al. (2009). Combined
targeted treatment to eliminate tumorigenic cancer stem cells in human pan-
creatic cancer. Gastroenterology 137, 1102–1113.
Neoplasia Vol. 14, No. 6, 2012 Chk1 Inhibition in Pancreatic Cancer Stem Cells Venkatesha et al. 525
